| Trial ID: | L4581 |
| Source ID: | NCT03118336
|
| Associated Drug: |
Empagliflozin 10mg Tab
|
| Title: |
Impact of Empaglifozine on Cardiac Ectopic Fat
|
| Acronym: |
EMPACEF
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Empagliflozin 10Mg Tab
|
| Outcome Measures: |
Primary: cardiac morphology, magnetic resonance imaging, 12 weeks|epicardial adipose tissue volume, magnetic resonance imaging, 12weeks | Secondary: myocardial triglyceride, proton magnetic resonance spectroscopy, 12weeks|hepatic triglyceride content, proton magnetic resonance spectroscopy, 12 weeks|myocardial PCr/ATP ratio, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Assistance Publique Hopitaux De Marseille
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
56
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2017-06-16
|
| Completion Date: |
2020-02-07
|
| Results First Posted: |
|
| Last Update Posted: |
2020-02-17
|
| Locations: |
Assistance Publique Hopitaux de Marseille, Marseille, France
|
| URL: |
https://clinicaltrials.gov/show/NCT03118336
|
